Cryoport, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
CYRX Community Narratives
Cold Chain Expansion Will Support Cell And Gene Therapies
Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery
Digitalization And Secular Trends Will Expand Biotech Cold Chain Services
Cold Chain Expansion Will Support Cell And Gene Therapies
View narrativeDigitalization And Secular Trends Will Expand Biotech Cold Chain Services
View narrativeRising Biopharma Regulations Will Crimp Expansion But Foster Recovery
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
CYRX: Rebounding Cell And Gene Therapy Demand Will Drive Future Upside
CYRX: Cell And Gene Recovery And Bioservices Edge Will Support Future Repricing
CYRX: Cell And Gene Therapy Recovery Will Test Service Margin Resilience
Snowflake Analysis
Cryoport, Inc. Key Details
- -0.81
- 47.08%
- -21.94%
- 38.1%
About CYRX
- Founded
- 1999
- Employees
- 688
- CEO
- Website
View website
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.